Company: TVRD
Filing Date: 2025-10-07
Form Type: S-1/A
Source: 0001104659-25-097519
Chunk: 296

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-10-07
Form: S-1/A
Chunk 296
---
 ​                                                                         | ​ |                  ​ |          ​ | ​ |    ​ |          ​ |
| Net loss per share attributable to common stockholders, basic and diluted | ​ |                  $ |      -1.53 | ​ |    $ |      -0.91 |
| Weighted-average common shares outstanding, basic and diluted             | ​ |                    | 19,193,932 | ​ |      | 19,134,096 |

The accompanying notes are an integral part of these financial statements.

F-5

TVARDI THERAPEUTICS, INC. STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT (Amounts in thousands, except share amounts)

| ​                                    
 ​                                    
 ​                                    
 ​                                    | ​ 
 ​ 
 ​ |                      ​ 
 Redeemable Convertible 
        Preferred Stock 
                 Shares | ​ | ​      
 Amount |      ​ | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ |            ​ 
            ​ 
 Common Stock 
       Shares | ​ 
 ​ | ​      
 ​      
 Amount |  ​ 
  ​ | ​ 
 ​ 
 ​ | ​          
 Additional 
 Paid-In    
 Capital    |     ​ | ​ 
 ​ 
 ​ | ​           
 ​           
 Accumulated 
 Deficit     |       ​ 
       ​ | ​ 
 ​ 
 ​ | ​                 
 Accumulated Other 
 Comprehensive     
 Loss              |   ​ | ​ 
 ​ 
 ​ | ​             
 Total         
 Stockholders’ 
 Deficit       |       ​ |
|:-------------------------------------|:--|-----------------------:|:--|:-------|-------:|:--|:--|-------------:|:--|:-------|---:|:--|:-----------|------:|:--|:------------|--------:|:--|:------------------|----:|:--|:--------------|--------:|
| Balances as of December 31, 2022     |   |             29,555,538 | ​ | $      | 85,503 | ​ |   |   19,127,914 | ​ | $      | 19 | ​ | $          |   446 | ​ | $           | -45,492 | ​ | $                 | -24 | ​ | $             | -45,051 |
| Exercise of stock options            |   |                      — | ​ |        |      — | ​ |   |        6,250 | ​ |